These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9743230)

  • 1. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice.
    Chiesa G; Parolini C; Canavesi M; Colombo N; Sirtori CR; Fumagalli R; Franceschini G; Bernini F
    Arterioscler Thromb Vasc Biol; 1998 Sep; 18(9):1417-23. PubMed ID: 9743230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.
    Warden CH; Hedrick CC; Qiao JH; Castellani LW; Lusis AJ
    Science; 1993 Jul; 261(5120):469-72. PubMed ID: 8332912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux.
    Lee M; Calabresi L; Chiesa G; Franceschini G; Kovanen PT
    Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1475-81. PubMed ID: 12231569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum.
    Fournier N; Atger V; Paul JL; Sturm M; Duverger N; Rothblat GH; Moatti N
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1283-92. PubMed ID: 10807744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. Particles containing various proportions of apolipoproteins A-I and A-II.
    Lagrost L; Dengremont C; Athias A; de Geitere C; Fruchart JC; Lallemant C; Gambert P; Castro G
    J Biol Chem; 1995 Jun; 270(22):13004-9. PubMed ID: 7768892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice.
    Franceschini G; Calabresi L; Chiesa G; Parolini C; Sirtori CR; Canavesi M; Bernini F
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1257-62. PubMed ID: 10323777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II.
    Marzal-Casacuberta A; Blanco-Vaca F; Ishida BY; Julve-Gil J; Shen J; Calvet-Márquez S; González-Sastre F; Chan L
    J Biol Chem; 1996 Mar; 271(12):6720-8. PubMed ID: 8636092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol homeostatic mechanisms in transgenic mice with altered expression of apoproteins A-I, A-II and A-IV.
    Kalopissis AD; Chambaz J
    Int J Tissue React; 2000; 22(2-3):67-78. PubMed ID: 10937356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport.
    Castro G; Nihoul LP; Dengremont C; de Geitère C; Delfly B; Tailleux A; Fievet C; Duverger N; Denèfle P; Fruchart JC; Rubin EM
    Biochemistry; 1997 Feb; 36(8):2243-9. PubMed ID: 9047326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
    Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
    Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice.
    Schultz JR; Gong EL; McCall MR; Nichols AV; Clift SM; Rubin EM
    J Biol Chem; 1992 Oct; 267(30):21630-6. PubMed ID: 1400473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
    Schultz JR; Verstuyft JG; Gong EL; Nichols AV; Rubin EM
    Nature; 1993 Oct; 365(6448):762-4. PubMed ID: 8413656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.
    Liu AC; Lawn RM; Verstuyft JG; Rubin EM
    J Lipid Res; 1994 Dec; 35(12):2263-7. PubMed ID: 7897323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI.
    Atger V; de la Llera Moya M; Bamberger M; Francone O; Cosgrove P; Tall A; Walsh A; Moatti N; Rothblat G
    J Clin Invest; 1995 Dec; 96(6):2613-22. PubMed ID: 8675626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice.
    Tailleux A; Bouly M; Luc G; Castro G; Caillaud JM; Hennuyer N; Poulain P; Fruchart JC; Duverger N; Fiévet C
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2453-8. PubMed ID: 11073852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractional efflux and net change in cellular cholesterol content mediated by sera from mice expressing both human apolipoprotein AI and human lecithin:cholesterol acyltransferase genes.
    Fournier N; Atger V; Paul JP; de la Llera Moya M; Rothblat G; Moatti N
    Atherosclerosis; 1999 Dec; 147(2):227-35. PubMed ID: 10559507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells.
    Fournier N; Cogny A; Atger V; Pastier D; Goudouneche D; Nicoletti A; Moatti N; Chambaz J; Paul JL; Kalopissis AD
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):638-43. PubMed ID: 11950703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis?
    Stein O; Dabach Y; Hollander G; Ben-Naim M; Halperin G; Stein Y
    Atherosclerosis; 1999 Jun; 144(2):367-74. PubMed ID: 10407497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.